own is late or long-term renal toxicity. [2] [3] [4] [5] [6] [7] [8] [9] [10][11] The renal toxicity described consists of a group of clinical signs including hypertension, anemia, and decreased glomerular filThe purpose of this study was to evaluate the effect of partial renal shielding used in conjunction with total tration rate (GFR) with occasional proteinuria and microscopic hematuria, and edema. Biopsies of the affected body irradiation (TBI) on the incidence of bone marrow transplantation nephropathy (BMT Np) seen as a late kidneys have a unifying aspect in that there is extreme subendothelial widening of the basement membranes, with sequelae after transplantation. Of 402 patients who have undergone bone marrow transplantation (BMT) at the endothelial cell dropout, glomerular arteriolar intimal thickening and atrophic tubules. Whether all the changes seen Medical College of Wisconsin (MCW) 157 were greater than 18 years of age, received 14 Gy TBI and survived on biopsy relate to the 'BMT nephropathy' (BMT Np) previously described has yet to be determined. What is unquesat least 100 days post-transplant. The incidence of BMT nephropathy was evaluated in these patients by dose to tionably true of the data to date is that the use of TBI appears to play a significant role in the development of the the kidneys. In the 72 patients who received 14 Gy TBI with no renal shielding, the actuarial risk of developing syndrome.
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Previously, our institution described the use of selective BMT Np at 2. years (30 months) post-BMT was 29 ± 7%. Sixty-eight patients received 14 Gy TBI with partial renal shielding in an effort to reduce the incidence of this late renal toxicity. 7 Here, we found an incidence of partial renal shielding of 15% (renal dose = 11.9 Gy), the actuarial risk of developing BMT Np was 14 ± 5%
BMT nephropathy of 26% in the unshielded patients at 18 months vs 6% in the shielded patients (P Ͻ 0.05). Shielding at 2. years. Seventeen patients received 14 Gy TBI with renal shielding of 30% (renal dose = 9.8 Gy); none of utilized at that time was a 70% transmission posterior/ anterior (PA)-only shield that decreased the total renal dose this group have developed BMT Np despite a median follow-up of over 2. years (985 days). The trend of from 14 Gy to 11.9 Gy. Since the partial shielding appeared effective but we were still experiencing some level of late decreasing BMT Np with increasing shielding is statistically significant (P = 0.012). Prognostic factors such as renal toxicity we doubled the shielding to a 40% transmission PA-only block to decrease the dose to the kidneys age, type of transplant and good-risk vs poor-risk disease status were evaluated and were similar in each to 9.8 Gy. Results of this change as well as long-term follow-up of the initial cohort of patients both renally blocked cohort of patients described above. We conclude that given the statistically significant benefit seen here in the and unblocked are the focus of this manuscript. reduced incidence of BMT Np by the use of selective renal shielding, this should be seriously considered for all patients who receive TBI, but especially for patients Materials and methods whose renal doses exceed 10 Gy. Keywords: renal shielding; TBI; neuropathy From July 1985 to February 1992, 402 patients have undergone BMT at the Medical College of Wisconsin. Diseases transplanted were mostly leukemias and lymphomas along with some benign conditions such as aplastic anemia, conBone marrow transplantation (BMT) is an effective treatgenital deficiency disorders and some solid tumors. One ment for an ever growing number of hematologic malighundred and fifty-nine of the patients were children (Ͻ18 nancies as well as solid tumors. 1 Complications related to years of age) and are excluded. Of the 243 adult patients, the transplant maneuver have become a significant concern 157 patients survived 100 days or longer and received our as more and more patients are becoming long-term surstandard conditioning regimen consisting of high-dose cytavivors of this treatment. One of the areas of toxicity that rabine (3 g/m 2 of body surface area every 12 h, for a total has been noted by a number of institutions including our of six doses), cyclophosphamide (45 mg/kg of body weight given 6 h after the second and fourth doses of cytarabine) and 14 Gy TBI dose (calculated at midplane at the level of reduce the renal dose to approximately 11.9 Gy which would correlate with the dose that most US centers use 12 and which is not routinely associated with BMT Np. We were still able to detect some (we felt unacceptable) level Results of BMT Np which we felt could be eliminated with further shielding. Since the initial shielding had not negatively
Of the 157 adult patients in this analysis, 72 had no renal affected our engraftment or relapse rates, further shielding blocking, 68 had single blocking and 17 had double blockof another 15% (double block) was instituted in February ing. In addition to the 14 Gy TBI as described, all patients of 1992. With the additional shielding, the dose to the kidalso received our standard high-dose cytarabine and cycloneys was reduced to 70% of the total 14 Gy or 9.8 Gy.
phosphamide.
14 Follow-up of patients was obtained through the charts Age ranges for the unblocked patients was 18-49 years for those patients who continue to have their care at our with a median of 31 years. For the single blocked patients institution and through both patients and their physicians the age range was 21-60 years with a median of 34 years. for those who are not routinely seen at our institution.
For the double blocked group the age range was 18-56 Therefore, no patient was lost to follow-up.
years with a median of 32 years. There was no statistical All patients had a complete medical evaluation prior to difference in age between the three groups. BMT including history and physical exams with vital signs, Follow-up times ranged from 107 to 3423 days with a height and weight. Laboratory evaluation included commedian of 1515 days for the unblocked patients, 1461 days plete blood count (CBC) with a differential and platelet for the single blocked group and 985 days for the double count, blood smear, blood urea nitrogen (BUN), serum creblocked group. All patients were followed with a minimum atinine, liver function tests, urinalysis and chest radiograph.
of annual updates for patients alive and several years Glomerular filtration rate (GFR) was calculated on all from transplant. patients pre-transplant via the Cockcroft-Gault formula.
13 Table 1 indicates the disease transplanted for in each All patients had normal renal function pre-transplant. group, with the majority of patients transplanted having leuPost-BMT patients routinely were followed with history kemia. There was no statistical difference in diseases transplanted amongst the three groups. and examinations, weight, vital signs and laboratory evaluTypes of transplants for each group are shown in Table 2 . ation including CBC with differential and platelet count, There is no statistical difference in types of transplants by serum creatinine, BUN, liver function tests, and chest radiorenal blocking groups with most common types of transgraphs. GFR was calculated on all patients post-transplant plants being from matched sibling and unrelated donors. with the Cockcroft-Gault formula. 13 Since age and type of transplant as well as diseases transDesignation of a patient as having BMT Np was only planted were not statistically different for the three groups done if the patient exhibited all three aspects of the syndrome previously described. All patients with the syndrome therefore had: (1) increased serum creatinine and BUN Table 2 Types of transplants performed along with decreased GFR; (2) anemia; and (3) suggest increasing incidence with increasing time after radiation. 15 Patient characteristics of the BMT Np patients are shown in Table 4 . As was true in the initial cohort of 14 Gy TBI patients treated without renal shielding the patients in both we also looked at disease status to understand any possible groups (shielded and unshielded) who develop the synprognostic differences between the three groups. Table 3 drome are a range of good-risk and poor-risk patients. shows the patients in the three groups divided into goodMedian age at transplant for BMT Np patients treated withrisk, poor-risk and 'benign' transplants. Good-risk patients out renal shielding was 31 years and 33 years for the are those transplanted with chronic myelogenous leukemia shielded group. Type of transplant likewise was similar (CML) in chronic phase, acute lymphocytic leukemia between the two groups with a related matched donor being (ALL) in first remission or acute non-lymphocytic leukemia the most common. Median time to the onset of BMT Np (ANLL) in first remission. All other patients are considered was 279 days for the unblocked patients and 289 days for poor risk except the patients transplanted for benign disthe blocked patients. Thus, the cohort of patients in each eases such as aplastic anemia. Although there are more group who developed BMT Np appear to be similar. poor-risk patients in the double blocked group 82 vs 59% Busulfan as an etiologic factor was evaluated in these for the unblocked and 69% for the single block, the differpatients. We initially used busulfan in our high risk patients ence does not meet statistical significance.
(4 mg/kg/day delivered over the 2 days prior to initiation Renal dysfunction (BMT Np) has been detected in a total of the cytarabine) during the time when we did not use of 20 patients of the 157 adults who survived 100 days. renal shielding (ie in patients whose renal dose was 14 Gy). Thirteen of the cases were detected in patients who received Busulfan in this cohort of patients was evaluated and it TBI without renal shielding and seven in patients who proved not to be an etiologic factor. 8 No patient in any of received TBI with single blocking (renal dose 11.9 Gy). To the two shielded groups has received busulfan as part of date none of the double blocked patients have developed their conditioning regimen. In the entire cohort of patients the syndrome despite reasonable length of follow-up. Actuevaluated in this study busulfan was not statistically assoarial risk of developing BMT Np is shown in Figure 2 . At ciated with an increase in BMT Np. 2. years the risk of BMT Np is 29.4 ± 7.1% for unblocked
Dates of onset of BMT Np were evaluated so as to patients, 14.1 ± 5.0% for single blocked patients and 0% address the question of adequate follow-up for the double for double blocked patients with a statistically significant blocked patients. Onset of BMT Np for all patients who difference between unblocked and double blocked patients developed the syndrome range from day 136 to day 794 (P = 0.046). If we group all blocked patients vs unblocked post-BMT with a median time to development of the synpatients there likewise is a statistical difference in the risk drome of 289 days. Median follow-up for the double blocked patients is 985 days which exceeds the range of time to development of the BMT Np. Survival rates, relapse rates, and engraftment rates have not been negatively affected by the institution of renal shielding, either single shielding (renal dose = 11.9 Gy) or double shielding (renal dose = 9.8 Gy) compared to no shielding.
Discussion
Total body irradiation has been an integral part of BMT since the first successful transplants in mice and rats. 12 Renal toxicity as a result of TBI was noted in both humans and in a rat model in the late 1980s, 5 ,9 yet documentation of renal toxicity after BMT has occurred since the late 1970s. 16 The relationship between dose of TBI and level of renal impairment has been the topic of many recent publications both clinically as well as in the laboratory. Renal shielding data from our institution appeared to show Auto = autologous; Syn = syngeneic; RM = related matched donor; RPM = related partial matched donor; Unr = unrelated donor; ALL-1st = acute lymphocytic leukemia 1st remission; ANLL 1st = acute non-lymphocytic leukemia 1st remission; CML-c = chronic myelogenous leukemia chronic phase; CLL = chronic lymphocytic leukemia; CML-ac = chronic myelogenous leukemia accelerated phase; NED = no evidence of disease; Anapl. Carc. = anaplastic carcinoma.
a benefit, but whether this effect would hold up with time nificantly different (P = 0.077) from our unblocked patients, is still about half of the incidence of this toxicity was the question. 7 Our initial cohort of patients treated to 14 Gy TBI without renal shielding shows an actuarial incicompared to the unshielded cohort. Further shielding as instituted in 1992 reduced the dose to the kidneys by dence of BMT Np of 29.4 ± 7.1% (Figure 2 ). With our first shielding of 15% we now have a 14.1 ± 5.0% (Figure 2) another 15% to under 10 Gy and has resulted in a 0% incidence of BMT Np in a group of 17 patients followed well incidence of BMT Np which although not statistically sig- past the time frame for developing the syndrome. Therefore, decreasing dose to the kidneys has been shown to statistically (P = 0.012 for trend analysis, Cox proportional hazards analysis, Figure 2 ) decrease the incidence of BMT Np. Other institutions have also noted this dose correlation with the level of BMT Np, but have not used selective renal shielding. 11 Miralbell et al 11 used three dose levels of TBI and showed a strong correlation between renal impairment and higher doses of TBI. A graph of the dose-response curve for BMT Np using data at 2.5 years from this study and the renal dysfunction data at 18 months from Miralbell is shown in Figure 4 . Overall, the incidence of renal dysfunction appears to be higher in the Miralbell data but this most likely represents the difference in definition of BMT Np syndrome. In the Miralbell data they included patients who had GVHD, did not require hypertension in their definition of renal impairment and included patients who survived less than 100 days.
11 But interestingly in the 10 Gy Miralbell et al 11
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Incidence of nephropathy Renal dose (Gy) TBI arm of the Miralbell data, the incidence of renal with their standard error.
Unquestionably there are multiple causes for the renal impairment seen after BMT. Certainly antifungal agents, aminoglycoside antibiotics, GVHD, infection, conditioning renal impairment seen, and therefore other nephrotoxins mentioned above must play some role. We and others have chemotherapy, chemotherapy prior to transplant as well as TBI all play some role in nephrotoxicity. In BMT Np, howtried to elucidate which of the nephrotoxins add to the radiation effect but there is still much more to be understood ever, the unifying feature appears to be the use of TBI, and modifying the total TBI dose delivered, or using selective in this area.
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BMT for aggressive leukemias and lymphomas continues renal shielding appears to statistically decrease the incidence. (Figures 2 and 3) . 11 The dose of radiation that the to be a mainstay of treatment with TBI as a part of the preparatory regimen. 1 For patients transplanted whose TBI kidneys receive, even with TBI doses as high as 14 
